Product
CD40.RBDv vaccin
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 1/2 Multicenter, Randomized Study of the Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.Status: Not yet recruiting, Estimated PCD: 2025-09-01